Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Zajecka

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
The Journal of Clinical Psychiatry|May 25, 2002
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combinationPhilip T Ninan, A John Rush, Paul Crits-Christoph, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|October 30, 2020
Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depressionMaurizio Fava, Erica Mazzone, Marlene Freeman, et al.
The Journal of Clinical Psychiatry|August 29, 2002
Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combinationJohn Zajecka, David L Dunner, Alan J Gelenberg, et al.
The Journal of Clinical Psychiatry|August 6, 2025
Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept StudyRichard C Shelton, Robert E Litman, Howard Hassman, et al.
Biological Psychiatry|September 6, 2005
Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trialA John Rush, Lauren B Marangell, Harold A Sackeim, et al.
The Journal of Clinical Psychiatry|July 17, 2025
Prognostic and Prescriptive Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial ReportScott T Aaronson, Charles R Conway, Charles Gordon, et al.
JAMA Psychiatry|June 6, 2019
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical TrialElla J Daly, Madhukar H Trivedi, Adam Janik, et al.
Biological Psychiatry|October 11, 2003
Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depressionAlan J Gelenberg, Madhukar H Trivedi, A John Rush, et al.
Journal of Affective Disorders|December 26, 2024
Suicide characteristics in patients with marked treatment-resistant major depressive disorder: A RECOVER trial reportVictoria C de Leon, Rebecca M Allen, João Quevedo, et al.
Brain Stimulation|April 4, 2024
Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial reportCharles R Conway, Scott T Aaronson, Harold A Sackeim, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Psychiatry|May 25, 2002
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combinationPhilip T Ninan, A John Rush, Paul Crits-Christoph, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|October 30, 2020
Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depressionMaurizio Fava, Erica Mazzone, Marlene Freeman, et al.
The Journal of Clinical Psychiatry|August 29, 2002
Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combinationJohn Zajecka, David L Dunner, Alan J Gelenberg, et al.
The Journal of Clinical Psychiatry|August 6, 2025
Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept StudyRichard C Shelton, Robert E Litman, Howard Hassman, et al.
Biological Psychiatry|September 6, 2005
Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trialA John Rush, Lauren B Marangell, Harold A Sackeim, et al.
The Journal of Clinical Psychiatry|July 17, 2025
Prognostic and Prescriptive Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial ReportScott T Aaronson, Charles R Conway, Charles Gordon, et al.
JAMA Psychiatry|June 6, 2019
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical TrialElla J Daly, Madhukar H Trivedi, Adam Janik, et al.
Biological Psychiatry|October 11, 2003
Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depressionAlan J Gelenberg, Madhukar H Trivedi, A John Rush, et al.
Journal of Affective Disorders|December 26, 2024
Suicide characteristics in patients with marked treatment-resistant major depressive disorder: A RECOVER trial reportVictoria C de Leon, Rebecca M Allen, João Quevedo, et al.
Brain Stimulation|April 4, 2024
Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial reportCharles R Conway, Scott T Aaronson, Harold A Sackeim, et al.
Pageof 4